JP2004339238A5 - - Google Patents

Download PDF

Info

Publication number
JP2004339238A5
JP2004339238A5 JP2004237765A JP2004237765A JP2004339238A5 JP 2004339238 A5 JP2004339238 A5 JP 2004339238A5 JP 2004237765 A JP2004237765 A JP 2004237765A JP 2004237765 A JP2004237765 A JP 2004237765A JP 2004339238 A5 JP2004339238 A5 JP 2004339238A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
composition according
daptomycin
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004237765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004339238A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004339238A publication Critical patent/JP2004339238A/ja
Publication of JP2004339238A5 publication Critical patent/JP2004339238A5/ja
Withdrawn legal-status Critical Current

Links

JP2004237765A 1998-09-25 2004-08-17 抗生剤の投与方法 Withdrawn JP2004339238A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000571937A Division JP4184607B2 (ja) 1998-09-25 1999-09-24 抗生剤の投与方法

Publications (2)

Publication Number Publication Date
JP2004339238A JP2004339238A (ja) 2004-12-02
JP2004339238A5 true JP2004339238A5 (enExample) 2006-01-12

Family

ID=26798675

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000571937A Expired - Lifetime JP4184607B2 (ja) 1998-09-25 1999-09-24 抗生剤の投与方法
JP2003149968A Withdrawn JP2003321389A (ja) 1998-09-25 2003-05-27 抗生剤の投与方法
JP2004237765A Withdrawn JP2004339238A (ja) 1998-09-25 2004-08-17 抗生剤の投与方法
JP2006258107A Withdrawn JP2006335773A (ja) 1998-09-25 2006-09-22 抗生剤の投与方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000571937A Expired - Lifetime JP4184607B2 (ja) 1998-09-25 1999-09-24 抗生剤の投与方法
JP2003149968A Withdrawn JP2003321389A (ja) 1998-09-25 2003-05-27 抗生剤の投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006258107A Withdrawn JP2006335773A (ja) 1998-09-25 2006-09-22 抗生剤の投与方法

Country Status (26)

Country Link
US (2) US6468967B1 (enExample)
EP (2) EP1115417B1 (enExample)
JP (4) JP4184607B2 (enExample)
KR (2) KR20010075327A (enExample)
CN (2) CN1530136A (enExample)
AT (1) ATE322280T1 (enExample)
AU (1) AU764348B2 (enExample)
BR (1) BR9914051A (enExample)
CA (1) CA2344318C (enExample)
CY (3) CY1105556T1 (enExample)
DE (3) DE122006000049I2 (enExample)
DK (2) DK1115417T3 (enExample)
ES (2) ES2603086T3 (enExample)
HK (1) HK1040363B (enExample)
HU (1) HU230656B1 (enExample)
IS (2) IS5890A (enExample)
LU (1) LU91254I2 (enExample)
NL (1) NL300232I2 (enExample)
NO (1) NO20011454L (enExample)
NZ (1) NZ510690A (enExample)
PL (2) PL203689B1 (enExample)
PT (2) PT1674107T (enExample)
RU (1) RU2363489C9 (enExample)
SI (2) SI1115417T1 (enExample)
TR (1) TR200100841T2 (enExample)
WO (1) WO2000018419A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
CN1425025A (zh) 1999-12-15 2003-06-18 卡比斯特制药公司 作为抗菌剂的新颖的脂肽
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
IL156394A0 (en) * 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CA2713989A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
KR101959873B1 (ko) 2008-10-07 2019-03-19 랩터 파마슈티컬스 인코포레이티드 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
US8809263B2 (en) * 2008-10-24 2014-08-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
BRPI0923567A2 (pt) 2008-12-22 2016-09-27 Cubist Pharm Inc agentes antibactericidas novos para o tratamento de infecções gram positivas
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
WO2011008193A1 (en) * 2009-07-13 2011-01-20 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
WO2011029059A1 (en) 2009-09-04 2011-03-10 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 1,3,4-□二唑及1,3,4-噻二唑β-內醯胺酶抑制劑
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
KR102237887B1 (ko) 2013-03-15 2021-04-07 멜린타 서브시디어리 코프. 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドSpero Potentiator, Inc. 新規カチオン性ペプチドspr741による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Similar Documents

Publication Publication Date Title
JP2004339238A5 (enExample)
JP2003321389A5 (enExample)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP7418475B2 (ja) バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用
CN102319246B (zh) 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物
JP2006335773A (ja) 抗生剤の投与方法
FI3006038T3 (fi) Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn
JP2012501349A5 (enExample)
JP2014510767A (ja) 細菌感染を治療するための方法
ES2842443T3 (es) Medicamento para el tratamiento de infecciones del pie diabético
CA3139942C (en) Medicament and use thereof for treating bacterial infections involving biofilm
CN1583166A (zh) 林蛙抗菌肽喷雾剂及其制备方法
EA048481B1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
RU2001111327A (ru) Способ применения антибиотиков
Lee et al. Orthopaedic infections: novel treatment strategies and evolving concepts
WO2024216287A1 (en) Uses of jak inhibitors in the management of sepsis and comorbidities
Purushotham et al. Statin: A boon in periodontal therapy
CN1256982C (zh) 达福普汀/奎奴普丁与头孢匹罗的组合形式
Pawar et al. Newer antibiotics for musculoskeletal infections
NZ745612B2 (en) Medicament for treatment of diabetic foot infections
Peerbooms et al. Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice
HK1058305B (en) Combinations of dalfopristine/quinupristine with cefpirome